• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

流式细胞术方法验证方案。

Flow Cytometry Method Validation Protocols.

机构信息

Cerba Research, Lake Success, New York.

AstraZeneca, Gaithersburg, Maryland.

出版信息

Curr Protoc. 2023 Aug;3(8):e868. doi: 10.1002/cpz1.868.

DOI:10.1002/cpz1.868
PMID:37606503
Abstract

Analytical method validation provides a means to ensure that data are credible and reproducible. This article will provide a brief introduction to analytical method validation as applied to cellular analysis by flow cytometry, along with practical procedures for four different types of validation. The first, Basic Protocol 1 (the limited validation protocol), is recommended for research and non-regulated laboratories. Next, Basic Protocol 2) presents a reasonable, fit-for-purpose validation approach appropriate for biopharma and research settings. Basic Protocol 3 addresses the type of validation performed in clinical laboratories for moderate-risk tests developed in house. Finally, Basic Protocol 4 describes the process that should be applied whenever a method is being transferred from one facility to another. All four validation plans follow the fit-for-purpose validation approach, in which the validation parameters are selected based on the intended use of the assay. These validation protocols represent the minimal requirement and may not be applicable for every intended use such as high-risk clinical assays or data to be used as a primary endpoint in a clinical trial. The recommendations presented here are consistent with the white papers published by the American Association of Pharmaceutical Scientists and the International Clinical Cytometry Society, as well as with Clinical Laboratory Standards Institute Guideline H62: Validation of Assays Performed by Flow Cytometry (CLSI, 2021). © 2023 Wiley Periodicals LLC. Basic Protocol 1: Limited validation Basic Protocol 2: Fit-for-purpose validation for biopharma and research settings Basic Protocol 3: Validation for moderate clinical risk laboratory developed tests Basic Protocol 4: Transfer validation.

摘要

分析方法验证提供了一种确保数据可信和可重现的手段。本文将简要介绍应用于流式细胞术进行细胞分析的分析方法验证,并提供四种不同类型验证的实用程序。第一种,基本方案 1(有限验证方案),推荐用于研究和非监管实验室。接下来,基本方案 2)提出了一种合理的、适用于生物制药和研究环境的有针对性的验证方法。基本方案 3 介绍了在内部开发的中等风险测试的临床实验室中进行的验证类型。最后,基本方案 4 描述了每当方法从一个设施转移到另一个设施时应应用的过程。所有四个验证计划都遵循有针对性的验证方法,其中验证参数是根据测定的预期用途选择的。这些验证方案代表了最低要求,可能不适用于每个预期用途,例如高风险临床测定或用作临床试验主要终点的数据。这里提出的建议与美国药物科学家协会和国际临床细胞化学协会发布的白皮书以及临床实验室标准协会指南 H62:流式细胞术测定的验证(CLSI,2021 年)一致。©2023 年 Wiley 期刊 LLC. 基本方案 1:有限验证 基本方案 2:适用于生物制药和研究环境的有针对性的验证 基本方案 3:中等临床风险实验室开发测试的验证 基本方案 4:转移验证。

相似文献

1
Flow Cytometry Method Validation Protocols.流式细胞术方法验证方案。
Curr Protoc. 2023 Aug;3(8):e868. doi: 10.1002/cpz1.868.
2
Flow Cytometry Method Validation Protocols.流式细胞术方法验证方案。
Curr Protoc Cytom. 2019 Jan;87(1):e53. doi: 10.1002/cpcy.53. Epub 2018 Nov 12.
3
Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines.流式细胞术检测方法的修改:基于CLSI H62指南的方法验证建议。
Cytometry B Clin Cytom. 2025 May;108(3):252-266. doi: 10.1002/cyto.b.22202. Epub 2024 Aug 21.
4
Validation of High-sensitivity Flow Cytometry for Reliable Immune Cell Analysis in Real-world Laboratory Settings.高敏流式细胞术在真实实验室环境中进行可靠免疫细胞分析的验证。
Ann Lab Med. 2023 Nov 1;43(6):620-624. doi: 10.3343/alm.2023.43.6.620. Epub 2023 Jun 30.
5
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
6
2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62).《2019年生物分析近期问题白皮书:美国食品药品监督管理局免疫原性指南、基因治疗、关键试剂、生物标志物及流式细胞术验证(第3部分 - 关于2019年美国食品药品监督管理局免疫原性指南、基因治疗生物分析挑战、关键试剂管理策略、生物标志物检测验证、流式细胞术验证及临床和实验室标准协会H62的建议)》
Bioanalysis. 2019 Dec;11(24):2207-2244. doi: 10.4155/bio-2019-0271. Epub 2019 Dec 10.
7
Panel Optimization for High-Dimensional Immunophenotyping Assays Using Full-Spectrum Flow Cytometry.采用全光谱流式细胞术的高维免疫表型分析检测面板优化。
Curr Protoc. 2021 Sep;1(9):e222. doi: 10.1002/cpz1.222.
8
Clinical biomarker validation.临床生物标志物验证
Bioanalysis. 2018 Jun 1;10(12):957-968. doi: 10.4155/bio-2018-0061. Epub 2018 Jun 20.
9
In Vitro Assays to Study PD-1 Biology in Human T Cells.在人 T 细胞中研究 PD-1 生物学的体外检测法。
Curr Protoc Immunol. 2020 Sep;130(1):e103. doi: 10.1002/cpim.103.
10
Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part II - preanalytical issues.基于细胞的荧光检测法验证:国际血液学标准化委员会和国际临床化学联合会实践指南 - 第二部分 - 分析前问题。
Cytometry B Clin Cytom. 2013 Sep-Oct;84(5):286-90. doi: 10.1002/cyto.b.21105.

引用本文的文献

1
A Quantitative Approach to Potency Testing for Chimeric Antigen Receptor-Encoding Lentiviral Vectors and Autologous CAR-T Cell Products, Using Flow Cytometry.一种使用流式细胞术对嵌合抗原受体编码慢病毒载体和自体嵌合抗原受体T细胞产品进行效力测试的定量方法。
Pharmaceutics. 2025 Feb 25;17(3):303. doi: 10.3390/pharmaceutics17030303.
2
Review of flow cytometry as a tool for cell and gene therapy.流式细胞术作为细胞和基因治疗工具的评价。
Cytotherapy. 2024 Feb;26(2):103-112. doi: 10.1016/j.jcyt.2023.10.005. Epub 2023 Nov 7.